Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
DBV Technologies is developing ViaskinÂŽ, an investigational proprietary technolog...
DBV Technologies is developing ViaskinÂŽ, an in...
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonan...
IRADIMED CORPORATION is a leader in the develop...
CARROT is a fitness app that rewards users financially for walking and meeting per...
CARROT is a fitness app that rewards users fina...
Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...
Neurocarrus is developing a breakthrough therap...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing comme...
BioDelivery Sciences International, Inc. (NASDA...
Ionis is a sustainably profitable, multi-product company with a pipeline of more t...
Ionis is a sustainably profitable, multi-produc...
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...
Spring Bank is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.